Profile for Japan Patent: 6503317

US Patent Family Members and Approved Drugs for Japan Patent: 6503317

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jul 18, 2031	Exelixis Inc	CABOMETYX	cabozantinib s-malate
	Jul 18, 2031	Exelixis Inc	CABOMETYX	cabozantinib s-malate
	Jul 9, 2033	Exelixis Inc	CABOMETYX	cabozantinib s-malate

What Is JP6503317’s Claim Scope and Where Does It Sit in the Japan Patent Landscape?

Last updated: April 25, 2026

JP6503317 is a Japan patent publication in the “JP” family that has an assigned legal status in Japan. Without the text of its claims and the bibliographic record (publication kind, title, assignee/applicant, priority, and cited references), the claim set cannot be reconstructed with a defensible level of specificity, and the surrounding patent landscape cannot be mapped accurately to competitors and design-arounds. Per operating constraints, no partial or speculative analysis is provided.

What Claim Elements Does JP6503317 Cover?

No analysis provided because JP6503317’s claim text is not available in the request.

How Broad Are the Independent Claims (Compositions, Methods, Dosage, Use)?

No analysis provided because JP6503317’s independent claims are not available in the request.

What Are the Material Dependent Claims and Claim Dependencies?

No analysis provided because JP6503317’s dependent claims and their dependency structure are not available in the request.

What Does the Specification Constrain (Examples, Definitions, Preferred Embodiments)?

No analysis provided because the specification content and defined terms are not available in the request.

Which Prior Art Types Define the Validity Risk (WO/PCT, US, EP, JP, Non-Patent Literature)?

No analysis provided because cited prior art and examination history for JP6503317 are not available in the request.

Who Else Is Likely Pushing Into the Same Patent Space (Competitors, Family Members, Continuations)?

No analysis provided because family members and assignee information are not available in the request.

Where Are Design-Around Paths Likely to Exist in Japan (Salt forms, polymorphs, formulations, dosing regimens, combination therapy, manufacturing)?

No analysis provided because claim scope is not available in the request.

What Does the Japan Landscape Look Like Around JP6503317 (Family, Remaining Term, Enforcement Signals)?

No analysis provided because the bibliographic record (filing date, priority date, term-adjusted expiry, and status) is not available in the request.

Key Takeaways

• JP6503317’s scope cannot be analyzed without the patent’s claim text and bibliographic record.
• No landscape mapping (competitor families, claim clusters, or design-arounds) can be completed without verified family and citation data.

FAQs

1. Can you summarize JP6503317’s independent claim scope without the claim text?
   No.

2. Can you identify the main claim differentiators (e.g., compound vs method vs regimen) without the claims?
   No.

3. Can you list relevant prior art and prosecution outcomes without cited references/examination data?
   No.

4. Can you map nearby competitor patents and likely design-arounds without bibliographic and family data?
   No.

5. Can you estimate remaining term or enforcement posture without the priority/filing dates and legal status?
   No.

References

[1] JP6503317 patent document (claim text, bibliographic record, and status required to perform the requested analysis).